Artelo Biosciences, Inc.
Artelo Biosciences, Inc.
Your view on ARTLW
Overview
What the company does, where it operates, and who runs it.
About Artelo Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gregory D. Gorgas
- Headquarters
- 505 Lomas Santa Fe, Solana Beach, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gregory D. Gorgas
- Headquarters
- 505 Lomas Santa Fe, Solana Beach, CA, US
Artelo Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing and commercializing therapeutic agents that interact with the endocannabinoid system. The company's portfolio of drug candidates features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is currently undergoing Phase 1b/2a clinical trials for the management of anorexia linked to cancer. Another promising candidate is ART12.11, a synthetic cannabidiol cocrystal being explored for its potential in treating inflammatory bowel disease and post-traumatic stress disorder (PTSD). Additionally, ART26.12, a fatty acid binding protein 5 inhibitor, is in development to address breast and prostate cancer, neuropathic and nociceptive pain, and various anxiety disorders, including PTSD. The company, initially incorporated in 2011 as Reactive Medical, Inc., was rebranded as Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Artelo Biosciences, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Artelo Biosciences, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Artelo Biosciences, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Artelo Biosciences, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Artelo Biosciences, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Artelo Biosciences, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Artelo Biosciences, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Artelo Biosciences, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Artelo Biosciences, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Artelo Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Artelo Biosciences, Inc.. Press releases and market coverage, newest first.